An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes

By Awada A.   Biganzoli L.   Cufer T.   Beex L.   Lohrisch C.   Batter V.   Hamilton A.   Nooij M.   Piccart M.  

European Journal of Cancer, Vol. 38, Iss. 6, 2002-01 ,pp. : 773-778

Elsevier

Access to resources Recommend Favorite

A Phase II Study of Paclitaxel in Advanced Breast Cancer Resistant to Anthracyclines

By Fountzilas G.   Athanassiades A.   Giannakakis T.   Bafaloukos D.   Karakousis K.   Dombros N.   Kosmidis P.   Skarlos D.  

European Journal of Cancer, Vol. 32, Iss. 1, 1996-01 ,pp. : 47-51

Elsevier

Access to resources Recommend Favorite

A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer

By Miles D.W.   Smith I.E.   Coleman R.E.   Calvert A.H.   Lind M.J.  

European Journal of Cancer, Vol. 37, Iss. 11, 2001-07 ,pp. : 1366-1371

Elsevier

Access to resources Recommend Favorite

A randomized phase II non-comparative study of pemetrexedcarboplatin and gemcitabinevinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients

By                    

International Journal of Oncology, Vol. 42, Iss. 5, 2013-01 ,pp. : 1778-1785

Spandidos Publications

Access to resources Recommend Favorite

A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer

By Dittrich Christian   Solska Ewa   Manikhas Alexey   Eniu Alexandru   Tjulandin Sergei   Anghel Rodica   Musib Luna   Frimodt-Moller Bente   Liu Yushan   Krejcy Kurt   Láng István  

Cancer Investigation, Vol. 30, Iss. 4, 2012-04 ,pp. : 309-316

Informa Healthcare

Access to resources Recommend Favorite